Loading...
Email Alert | RSS

Table of Content

    10 August 2020, Volume 42 Issue 8
    • Guideline·Standard·Consensus
      Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC)
      Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis
      Chinese Journal of Antituberculosis. 2020, 42(8):  761-768.  doi:10.3969/j.issn.1000-6621.2020.08.001
      Abstract ( 2843 )   HTML ( 99 )   PDF (1555KB) ( 1511 )   Save
      Figures and Tables | References | Related Articles | Metrics

      As one of the countries with high burden of tuberculosis worldwide, China possesses a huge number of tuberculosis cases and latent tuberculosis infections (LTBI), which brings great challenges to the prevention and control of tuberculosis. Effective identification of tuberculosis and LTBI is of great significance to control the epidemic situation of tuberculosis. The diagnosis of sputum-negative pulmonary tuberculosis, especially LTBI, depends on the immunological diagnostic method of tuberculosis infection. The current immunological detection methods of tuberculosis infection are mainly tuberculin skin test (TST), interferon-gamma release assays (IGRA) and antigen-antibody detection. On the basis of the current three methods, we have developed new products and techniques for the diagnosis of LTBI and tuberculosis-recombinant Mycobacterium tuberculosis fusion protein (EC) (the product name is the Chinese general name of the drug determined by the State Pharmacopoeia Commission, and “EC” refers to the recombinant fusion protein “Mycobacterium tuberculosis early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10)”) (short for “EC”), featuring simple operation, high sensitivity and specificity. At present, phase Ⅰ, Ⅱ and Ⅲ clinical trials of EC have been completed. In the screening of 1559 healthy people in the phase Ⅲ clinical trial, it was found that the detection results of EC and IGRA had quite high specificity and consistency(88.77%). The clinical study of 791 patients diagnosed with tuberculosis showed that the detection results of EC, tuberculosis infected T lymphocyte spot test (T-SPOT.TB) and tuberculin pure protein derivative (TB-PPD) had good sensitivity and quite high consistency among them. In the study of 479 patients uninfected Mycobacterium tuberculosis, the negative coincidence rate of EC and T-SPOT.TB was high (reaching 88.20% and 93.17%). In the study of the effect of BCG vaccine on the test results, it was found that EC and T-SPOT.TB were basically not affected by BCG. In the clinical study of 394 patients diagnosed with non-tuberculous diseases, it was found that the negative coincidence rate of EC and T-SPOT.TB was quite high, and the consistency was good (87.21%). Based on the fact that EC is safe and effective in the diagnosis of tuberculosis infection, EC has passed the drug examination and approval of the State Drug Administration and is approved to be listed on the market. After extensively soliciting the opinions of experts in the fields of tuberculosis prevention and control, clinical and research and combining with the clinical trial results of EC, the expert consensus on the clinical application of EC has been formed on the basis of systematically summarizing the application characteristics of relevant technologies and methods. This consensus introduces the recommendations for the clinical application of EC, including the target users, method of application, the interpretation of the results, as well as the clinical significance and scope of use.

      Expert consensus on off-label use of drugs for non-tuberculous mycobacteria
      Beijing Chest Hospital, Capital Medical University, Non-tuberculous Mycobacterial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis
      Chinese Journal of Antituberculosis. 2020, 42(8):  769-787.  doi:10.3969/j.issn.1000-6621.2020.08.002
      Abstract ( 1029 )   HTML ( 31 )   PDF (1445KB) ( 824 )   Save
      References | Related Articles | Metrics

      For the treatment of non-tuberculous mycobacterial disease drugs or no indication, or over-treatment, over-dose, etc. The Non-tuberculous Mycobacterial Branch of the Chinese Antituberculosis Association organized relevant experts on treatment drugs such as macrolides, rifamycin, aminoglycosides, fluoroquinolones, β-lactams, tetracyclines, linezolid, clofazimine, bedaquiline, trimethoprim-sulfamethoxazole and other drugs for non-tuberculous mycobacterial disease to reach a consensus, looking forward to providing guidance to clinicians.

      Special Articles
      To formulate prevention and control strategy for latent tuberculosis infection population in China
      ZHU Li-mei, CHEN Can-can, CHEN Wei, HU Xiao-guang, ZHANG Ya-nan, MA Jun-yang
      Chinese Journal of Antituberculosis. 2020, 42(8):  794-798.  doi:10.3969/j.issn.1000-6621.2020.08.004
      Abstract ( 756 )   HTML ( 28 )   PDF (1166KB) ( 492 )   Save
      References | Related Articles | Metrics

      To strengthen the management of latent tuberculosis infection (LTBI) populations is one of the important ways to achieve the goal of tuberculosis (TB) prevention and control. Lower contribution rate of high-risk population in the incidence of TB, unclear risk characteristics, limited screening methods, and difficulty in preventive drug promotion, etc., are the problems of China’s LTBI management. A prevention and control strategy for LTBI population is proposed to improve the situation. We wonder to reduce the harm of TB to the whole society by health education, especially guiding and the adopting suitable public health measures for the whole population by national policy. As an important supplement to the management strategy of patients and high-risk population, scientific and feasible population management strategy of LTBI, including making full use of current innovative technologies to carry out active screening, population monitoring and other measures, in order to formulate TB infection control plans and policies in China, and it is important to gradually achieve the goal of “End TB”.

      Original Articles
      Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC)
      YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang
      Chinese Journal of Antituberculosis. 2020, 42(8):  799-806.  doi:10.3969/j.issn.1000-6621.2020.08.005
      Abstract ( 788 )   HTML ( 23 )   PDF (833KB) ( 428 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To investigate the stability of the bulk storage, finished products storage; in-use stability; and efficacy of recombinant Mycobacterium tuberculosis fusion protein(EC)(Chinese generic name of the drug determined by the National Pharmacopoeia Committee, EC stands for recombinant fusion protein 6-kDa (Relative molecular mass of 1 kDa is 1000) early secreted antigenic target protein (ESAT-6) and the 10-kDa culture filtrate protein (CFP-10))(Hereinafter referred to as “EC”). Methods (1) Bulk storage stability study:3 batches of bulk was placed at -70℃ and observed for 0-36 months, samples were taken in the 0, 3, 6, 9, 12, 18, 24, 36 months for sensitization effect test, identification test, titer test and tests of isoelectric point, molecular weight, protein content, purity (Electrophoresis), etc. In the sensitization effect test, guinea pigs were divided into experimental group (Injection of EC bulk) and control group (Injection of stabilizer), and the animal reaction after injection was observed, where there should be no difference between the two groups. In identification test, BCG sensitized guinea pigs were intradermally injected with EC and tuberculin pure protein derivative(TB-PPD) respectively. The skin test results of guinea pigs were observed and measured. The skin test results of EC should be negative (The average diameter of induration or redness <5 mm), while the skin test results of TB-PPD should be positive (The average diameter of induration ≥5 mm). In titer tests, 6 MTB sensitized guinea pigs, each was injected with 3 EC injections in different dilutions and 3 control injections, observe and measure the test results of guinea pig skin tests, the ratios of the sum of the average diameter of induration or redness of the local reaction to EC bulk injections in different dilutions and that to control injections, should be 1.0±0.2. The isoelectric points should be 3.5-5.3; the molecular weights should be (23±2.0) kDa; the protein contents should be not less than 450.0μg/ml, and the purities (electrophoresis method) should not be less than 95.0%. (2) Final products storage stability study: The final products were stored at 37℃ and 2-8℃ for observed 0-28 days and 0-36 months, respectively. On day 0, 7, 14, 21, 28 at 37℃ and month 0, 3, 6, 9, 12, 18, 24, 36 at 2-8℃, samples were taken for identification test, titer test and pH value, phenol content, etc. For the identification test, test method and result determination see ‘EC bulk’. For titer test, 4 guinea pigs, each was injected with EC final products and control injection respectively, the measurement methods, and the ratios of the sum of the average diameter determination see ‘EC bulk’, pH values should be 6.8-7.4, phenol contents should not be higher than 3.0g/L. (3) Final products in-use stability study: After opening, the final products were placed at two conditions: (25±2)℃, (60±5) % humidity, and (40±2℃), (75±5) % humidity, observe for 50min, to investigate the in use stability, samples were taken at 0, 10,20,30,40,50min, for identification test, titer test and pH value, osmotic pressure molar concentration, test methods and result determination see ‘EC final products’, osmotic pressure molar concentrations should be (280.0±68.0) mOsmol/kg. The stability of the products will be judged according to whether the regular sampling test results meet EC quality standards, it will provide basis for the determination of the validity period of EC bulk and final products, and the in-use effective period of EC final products. Results (1) For EC bulk stored at -70℃, observed for 0-36 months: At each time point, the sensitization effect tests showed no difference between the experimental group and the control group. The identification test results were negative for EC bulk and positive for TB-PPD; for titer test, the ratios of the sum of the average diameter of induration or redness of EC bulk and control injections were 0.9-1.1. The isoelectric points were 3.7-5.2. The molecular weights were (23.2-24.2) kDa. The protein contents were (501.6-616.7)μg/ml, and the purities (electrophoresis method) was 100.0%. (2) For EC final products stability study: At each time point, the identification test results were negative for EC bulk and positive for TB-PPD. For titer test, the ratios of the sum of the average diameter of induration or redness of EC final products and control injections were 0.9-1.0. pH values were 7.1-7.4 and phenol contents were (2.6-2.9) g/L. (3) For final products in-use stability study: At each time point, the identification test results were negative for EC bulk and positive for TB-PPD. For titer test, the ratios of the sum of the average diameter of induration or redness of EC final products and control injections were all 1.0. pH values were 7.1-7.2. Osmotic pressure molar concentrations were (302.4-307.4)mOsmol/kg. Conclusion EC bulk is quality stable to be stored for 36 months at -70℃. EC final products are quality stable to be stored for 28 d at 37℃ and 36 months at 2-8℃. After opening, the final products are quality stable for 50min.

      Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC)
      ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang
      Chinese Journal of Antituberculosis. 2020, 42(8):  807-813.  doi:10.3969/j.issn.1000-6621.2020.08.006
      Abstract ( 1275 )   HTML ( 21 )   PDF (1484KB) ( 384 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective By perform the immunological characteristics and preclinical animal safety study of recombinant Mycobacterium tuberculosis fusion protein ESAT-6-CFP-10 (Which is the Chinese generic name of the drug determined by the National Pharmacopoeia Committee, EC stands for recombinant fusion protein 6 kDa early secretory antigenic target (ESAT-6) and 10 kDa culture filtrate protein (CFP-10))(EC), to discuss its clinical application prospect. Methods (1) Immunological characteristics study: 6 female guinea pigs were sensitized with Mycobacterium tuberculosis live bacteria solution (H37Ra), 5 weeks later, intradermally injected 0.2ml EC (2.5μg/ml); and 4 female guinea pigs were sensitized with live BCG bacteria solution, 5 weeks later, intradermally injected 0.2ml EC (20μg/ml). Observed the mean diameter of the induration or redness reaction ((longitudinal diameter + transverse diameter)/2, ≥5 mm is considered positive, <5 mm is considered negative). (2) Acute toxicity test: 80 ICR mice (Institute of Cancer Research (USA)) were divided into single intramuscular injection group and intradermal injection group, each group with 40, half male and half female. And then, each group was divided into 4 subgroups, each subgroup with 10, half male and half female. High dose subgroup was injected with EC of 53.61μg/0.1ml, while low does subgroup was 0.2μg/0.1ml, solvent control subgroup was injected with diluent (0.1ml) of EC, and the blank control subgroup would receive no injection. These mice were observed for abnormality in appearance, motor function, body weight, various organs and skin of injection site. (3) Guinea pig systemic active allergy test: 24 guinea pigs were divided into 4 subgroups, each subgroup with 6, half male and half female. Subgroups were injected intraperitoneally every other day with EC of 5μg/kg (high dose), 0.5μg/kg (low dose), bovine Serum Albumin, and 0.9%NaCl (2 ml) respectively, after 3 successive times, the sensitization finished. On the 12th day after the last sensitization, the sensitized guinea pigs were irritated by rapid intravenous injection with 2 times doses or more sensitizer. During sensitization, each animal’s symptom was observed daily and the body mass of each animal was measured on the first and last sensitization and irritation days. (4) Intradermal irritation experiment: 6 New Zealand rabbit was injected intradermally with EC of 10μg(0.2 ml)/spot, 5 spots on each side, observed the intradermal irritation reaction on the injection site. Results (1) Immunological characteristics study: In 4 BCG live bacteria solution sensitized guinea pigs, the skin tests with EC showed 0 positivity, and in 6 live MTB (H37Ra) sensitized guinea pigs, skin tests showed 6 with positivity. (2) Acute toxicity test: No significant acute toxic reactions or acute target organ poisoning were observed in all mice. The mean body masses of EC intradermally injected mice group at the time of: before injection, 1 d,3 d,5 d,7 d,8 d,10 d,12 d,14 d post injection, respectively in high dose subgroup and low dose subgroup were (20.6±1.3) g-(24.9±2.1) g,(20.5±1.6) g-(26.0±3.1) g;and compare to blank control group ((21.0±1.1) g-(25.3±2.3) g) in the corresponding time, the t values were 0.571-0.392;0.695-0.615;while P values were 0.575-0.700;0.496-0.546, respectively; the differences were not statistically significant. The mean body masses of EC intramuscularly injected mice group at the time of: before injection, 1 d,3 d,5 d,7 d,8 d,10 d,12 d,14 d post injection, respectively in high dose subgroup and low dose subgroup were (21.0±1.5) g-(26.2±1.9) g,(20.5±2.1) g-(25.8±3.8) g;and compare to blank control group ((21.2±1.7) g-(25.8±3.1) g) in the corresponding time, the t values were 0.360-0.318;0.900-0.006;while P values were 0.723-0.754;0.380-0.995;the differences were not statistically significant. (3) Guinea pig systemic active allergy test: no allergic reactions in guinea pigs. The average body mass of guinea pigs in the high,the low dose group of EC and 0.9%NaCl injected negative control group at the time of the first sensitization, the last sensitization, irritation and post irritation were (327.5±24.3) g,(347.2±32.7) g,(402.2±34.9) g;(331.3±26.7) g,(346.2±32.0) g,(411.3±38.9) g;(329.5±27.4) g,(348.3±27.0) g,(399.4±25.4) g, respectively. Compare to 0.9%NaCl injected negative control group, the t values were 0.328,0.181,0.284;0.474,0.366,0.875;while P values were 0.757,0.864,0.788;0.656,0.730,0.422, respectively, the differences were not statistically significant. (4) Intradermal irritation experiments in rabbits: for rabbits with single intradermal injection with 10μg(0.2 ml)/spot EC, no significant irritation reaction were observed. Conclusion EC is able to differentiate tuberculosis infection from BCG immunization. With good preclinical safety, it is expected to be applied in the in vivo diagnosis for Mycobacterium tuberculosis infection.

      Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein
      ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang
      Chinese Journal of Antituberculosis. 2020, 42(8):  814-820.  doi:10.3969/j.issn.1000-6621.2020.08.007
      Abstract ( 600 )   HTML ( 7 )   PDF (835KB) ( 414 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To establish the quality standard for recombinant Mycobacterium tuberculosis fusion protein (EC)(Which is the Chinese generic name of the drug determined by the National Pharmacopoeia Committee, EC stands for recombinant fusion protein 6 kDa early secretory antigenic target (ESAT-6) and 10 kDa culture filtrate protein (CFP-10)) stock solution and recombinant EC. Methods Six batches of recombinant EC stock solution, 11 batches of recombinant EC, 21 no specific pathogen (SPF) white guinea pigs with the weight of 300-400 g, viable BCG bacterial solution (1mg/ml), and viable bacteria solution of Mycobacterium tuberculosis attenuated strain H37Ra (2mg/ml) were selected to establish the quality standard of the recombinant EC stock solution, including residual antibiotic activity detection, sensitization effect test, potency determination and animal identification experiment. Establishment of quality standards for recombinant EC included identification experiment and potency determination. Six consecutive batches of the recombinant EC stock solution and 11 batches of the recombinant EC were tested using to the established quality standard, to verify the applicability and feasibility of the standard. Results 1. Data of the residual antibiotic activity detection in the recombinant EC stock solution: (1) Specific experiment: the absorbance (A) value of PBS buffer was 1.736, and that of kanamycin standard (0.0 ng/ml) was 2.178; (2) Linear and range experiments: the determination coefficient R2 of goodness of fit of regression equation for three consecutive experiments was greater than 0.99 when kanamycin ranged between 0.5 and 40.5 ng/ml; (3) Accuracy test: the recovery rates of residual kanamycin in three consecutive batches of recombinant EC were 112.163%, 117.285% and 103.527%, respectively; (4) Repeatability test: the relative standard deviation (RSD) of A values of repeatability test in three consecutive batches of recombinant EC were 5.59%, 9.18% and 8.07%, respectively; (5) Intermediate precision test: kanamycin residues of three consecutive batches of the recombinant EC stock solution were detected by the same experimenter at different times and by different experimenters at the same time, and the results were all less than the quantitative limit of 0.5 ng/ml; (6) Durability test: the change of reading time (0, 5, 10min) had no effect on the detection of kanamycin residues in recombinant EC stock solution, and kanamycin residues were all less than the quantitative limit of 0.5 ng/ml. 2. Potency determination of recombinant EC stock solution: when the dilutions were 1μg/ml (5 U/ml), 2.5μg/ml (12.5 U/ml), 5μg/ml (25 U/ml) and 10μg/ml (50 U/ml), the average diameters and sum ratios of the average diameter of induration or redness of 2 batches of recombinant EC stock in animal experiments were (15.17±0.88) mm, (13.67±1.25) mm, 1.11 (91.00/82.00); (17.00±1.76) mm, (16.08±1.32) mm, 1.06 (102.00/96.50); (19.58±1.69) mm, (17.67±1.37) mm, 1.11 (117.50/106.00); (20.75±1.57) mm, (20.25±1.17) mm, 1.02 (124.50/121.50), respectively. 3. Animal identification experiment for recombinant EC stock solution: the average diameters of induration or redness in 3 consecutive batches of recombinant EC were 0, while the average diameter of induration was (15.13±5.06) mm in TB-PPD. 4. Identification test of the recombinant EC: the average diameters of induration or redness in 3 consecutive batches of recombinant EC were 0, while the average diameter of induration was (16.50±2.65) mm in TB-PPD. 5. Quality standard verification: (1) Recombinant EC stock solution: the results of residual antibiotic activity were all lower than the quantitative limit of 0.5 ng/ml; the sensitization effect test results showed that there was no significant difference in the local reactions of the injection site and no systemic reaction were found; the results of potency determination showed that in different dilutions (2.5μg/ml (12.5 U/ml), 5μg/ml (25 U/ml), 10μg/ml (50 U/ml)), the average diameter of local induration or redness reaction of each dilution were all ≥8 mm 24 h after injection. The ratio of the sum of local induration or redness reaction of the corresponding controls was 0.9±0.1. Results of animal identification experiment showed that the skin tests of BCG viable bacteria sensitized guinea pigs were all negative (mean diameter of induration or redness <5 mm), while the skin tests of guinea pigs with TB-PPD were positive (mean induration diameter ≥5 mm); (2)Tests for the recombinant EC: the results showed that the skin test were all negative (mean induration or redness diameter <5 mm), while TB-PPD were positive (mean induration diameter ≥5 mm). Conclusion The established quality standards could be used for verification in recombinant EC stock solution and recombinant EC.

      Screening for latent tuberculosis infection and identification of BCG vaccination by recombinant Mycobacterium tuberculosis 11 kDa
      ZHAO Ai-hua, KANG Wan-li, WANG Guo-zhi, GAO Zheng-lun, DU Wei-xin, LU Jin-biao, SHEN Xiao-bing, SU Cheng, XU Miao, ZHENG Su-hua
      Chinese Journal of Antituberculosis. 2020, 42(8):  821-825.  doi:10.3969/j.issn.1000-6621.2020.08.008
      Abstract ( 634 )   HTML ( 15 )   PDF (816KB) ( 304 )   Save
      References | Related Articles | Metrics

      Objective To evaluate the application of recombinant Mycobacterium tuberculosis 11 kDa protein (relative molecular mass 11000) in screening for latent tuberculosis infection and identification of BCG vaccination. Methods Recruited volunteers in Changping District, Huairou District, and Daxing District of Beijing from July 2014 to March 2016, signed informed consent, and recruited 3001 healthy volunteers after qualified medical examination, using the Mantoux method to carry out the two-arm skin test of recombinant 11 kDa protein and TB-PPD, and intradermal injection of different forearms 0.1ml of recombinant 11 kDa protein (10μg/ml) and 0.1ml of tuberculin pure protein derivative (TB-PPD) (50 U/ml), and observed the skin reaction 72 hours after injection. Before the skin test, venous blood of volunteers was collected for in vitro interferon gamma release assay (IGRA) detection. The “consistency rate (%)” and “the first-order agreement coefficient (AC1)” were used to compare the results of the recombinant 11 kDa protein skin test, TB-PPD test and IGRA results. Three thousand and one volunteers were tested by 3 methods, choosing 475 of subjects with negative results of all the three test, to sign an informed consent. According to the random number table double-blind principle (in the ratio of 2∶1), they were vaccinated with BCG (318 subjects) and placebo (147 subjects). After 3 months of inoculation, they were again subjected to parallel recombinant 11 kDa protein skin test, TB-PPD skin test and IGRA. Results In the screening of latent tuberculosis infection in healthy volunteers, the difference between 11 kDa (32.2%, 966/3001) and IGRA (34.4%, 1033/3001) results was statistically significant (χ2=22.787, P<0.001); the consistency rate of IGRA and 11 kDa was 93.4% (2804/3001), and the Gwet’s AC1 value was 0.882 (95%CI=0.866-0.898), the two had good consistency. Compared with the result of 11 kDa (32.2%, 966/3001) and TB-PPD (47.7%, 1430/3001), the positive rate of TB-PPD was significantly higher than that of 11 kDa. The difference between the result of TB-PPD and 11 kDa was very significant (χ2=182.146, P<0.001). The consistency rate of TB-PPD and 11 kDa was 60.6% (1819/3001), and its Gwet’s AC1 value was 0.243 (95%CI=0.207-0.279). The consistency between the two was poor. In the BCG vaccination identification study, there was no statistically significant difference between the 11 kDa (1.3%, 4/318) and IGRA (3.1%, 10/318) results in the vaccination group (χ2=2.571, P=0.109). The agreement rate was 95.6% (304/318), and the Gwet’s AC1 value was 0.954 (95%CI=0.929-0.979), the two had good consistency. The difference between 11 kDa (1.3%, 4/318) and TB-PPD (56.3%, 179/318) results was very significant (χ2=167.350, P<0.001). The consistency rate of TB-PPD and 11 kDa was 42.5% (135/318), and its Gwet’s AC1 value was 0.025 (95%CI=-0.106-0.155). The consistency between the two was poor. In the placebo group, there was no significant difference in the positive rate of 11 kDa (4.1%, 6/147) and IGRA (1.4%, 2/147) (χ2=2.667, P=0.109); the consistency rate was 95.9% (141/147), and the AC1 value was 0.957 (95%CI=0.921-0.993), which had good consistency. The positive rate of TB-PPD (17.7%, 26/147) was higher than that of 11 kDa (4.1%, 6/147), the difference was statistically significant (χ2=15.385, P<0.001), the consistency rate was 82.3% (121/147), and the AC1 value was 0.781 (95%CI=0.690-0.871). Conclusion Recombinant Mycobacterium tuberculosis 11 kDa protein has a good consistency with IGRA in screening for latent tuberculosis infection and BCG vaccination, suitable for large-scale screening, and can be used as one of the candidate diagnostic reagents for the screening of latent infected persons and the differentiation of BCG vaccination.

      Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation
      DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao
      Chinese Journal of Antituberculosis. 2020, 42(8):  826-831.  doi:10.3969/j.issn.1000-6621.2020.08.009
      Abstract ( 913 )   HTML ( 4 )   PDF (1325KB) ( 376 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To develop a national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation, in which the recombinant Mycobacterium tuberculosis fusion protein (EC) (Which is the Chinese generic name of the drug determined by the National Pharmacopoeia Committee, EC stands for recombinant fusion protein 6 kDa early secretory antigenic target (ESAT-6) and 10 kDa culture filtrate protein (CFP-10)) bulk was used as the material. Methods The EC bulk with qualified purity determined by electrophoresis and HPLC was weighed, packaged and freeze-dried accurately to make as national reference candidate, and the content of protein and moisture was further verified. The candidate of different dilution was injected into guinea pig infected with live Mycobacterium tuberculosis, a proper dilution was designated according to the reaction of skin test. And then the applicability of national reference candidate was evaluated preliminarily through the potency testing of the recombinant EC bulk. Stability of candidate storing in -20℃ for 24 months was also evaluated. Results The purity of EC stock was 100.00% by electrophoresis, and 95.33% by HPLC. The protein content of national reference candidate was 508μg/bottle, moisture content was 1.57%, and sub-packaging precision was controlled within ±1%. There was a good linear relationship in the dose response curve (R2=0.9944)when the dilution of reference candidate was 2.5 μg/ml (12.5 U/ml), 5 μg/ml (25 U/ml), and 10 μg/ml (50 U/ml). Assaying the national reference candidate by EC stock, the trend of both logarithmic reaction curve was corresponding (R2=0.9878,R2=0.9643), and ratio met 1.0±0.2. Method validation showed that the trend of logarithmic reaction curve of national reference candidate and EC bulk was corresponding (R2=0.9999,R2=0.9815), and ratio met 1.0±0.2. The result of stability study showed that national reference candidates were stable when they were kept at -20℃ for 24 months. Conclusion The candidate meets the demand of national reference in terms of purity, protein content, moisture content and uniformity. It will be possible to be used in the standization of potency assay of the freeze-dried recombinant Mycobacterium tuberculosis allergen.in a proper dilution. After method validation and stability evaluation, the candidate shows good performance, which will provide a good basis for the application of national reference

      Preliminary study on establishing the diagnostic model for smear negative tuberculosis and stage Ⅰ/Ⅱ sarcoidosis with hilar/mediastinal lymphadenopathy and positive T-SPOT.TB results
      CHEN Feng-fang, MA Jun, HUANG Jin, YIN Hong-yun, SHA Wei, YANG Guang-hong, FENG Yong-hong
      Chinese Journal of Antituberculosis. 2020, 42(8):  832-837.  doi:10.3969/j.issn.1000-6621.2020.08.010
      Abstract ( 814 )   HTML ( 13 )   PDF (895KB) ( 399 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To establish diagnostic models of mediastinal lymph node tuberculosis patients and stage Ⅰ/Ⅱ sarcoidosis patients, who were both positive in tuberculosis infection T lymphocyte spot (T-SPOT.TB) test and with negative sputum smear, to improve the clinical sensitivity and specificity of the differential diagnosis of the two diseases. Methods Clinical and laboratory examination data of 100 mediastinal lymph node tuberculosis and 50 stage Ⅰ/Ⅱ sarcoidosis patients diagnosed by chest CT examination and biopsy histopathology (nstage Ⅰ=8, nstage Ⅱ=42) from Shanghai Pulmonary Hospital between January 2013 and December 2018 were retrospectively analyzed, their T-SPOT.TB test were positive and were not be treated with glucocorticoid or anti-tuberculosis treatment, in a logistic regression model for differential diagnosis of the two diseases was established. The diagnostic efficiency of the model was evaluated by the area under the ROC curve (AUC), sensitivity and specificity. Results Multivariate unconditional logistic regression analysis showed that serum angiotensin-converting enzyme (SACE) (Wald χ2=5.826, P=0.016, OR (95%CI)=0.968 (0.942-0.994)), erythrocyte sedimentation rate (ESR) (Wald χ2=5.583, P=0.018, OR (95%CI)=1.036 (1.006-1.068)) and lymphocyte count (Wald χ2=4.074, P=0.044, OR (95%CI)=4.487 (1.044-19.279)) were independent factors related for the identification of mediastinal lymph node tuberculosis and stageⅠ/Ⅱ sarcoidosis. The established logistic regression model was logit (P)=-0.418-0.033×SACE+0.036×ESR+1.501×Lym. The AUC of diagnostic efficiency of the model were 0.850 (95%CI: 0.773-0.927), the optimal cut-off value was 1.307, the sensitivity was 82.4%, and specificity was 80.9%, respectively. Conclusion The diagnostic model established in this study has high sensitivity and specificity, and is auxiliary for the differentially diagnose of mediastinal lymph node tuberculosis and stageⅠ/Ⅱsarcoidosis with positive T-SPOT.TB test.

      Individualized treatment of drug-resistant osteoarticular tuberculosis based on phenotypic and molecular drug susceptibility tests and its short-term effectiveness evaluation
      SHENG Jie, ZHU Yang, Dilixiati·Abulizi , TANG Wei, GU Fu-ding, SONG Xing-hua
      Chinese Journal of Antituberculosis. 2020, 42(8):  838-844.  doi:10.3969/j.issn.1000-6621.2020.08.011
      Abstract ( 540 )   HTML ( 6 )   PDF (1523KB) ( 229 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To evaluate short-term effectiveness of individualized treatment under the guidance of phenotypic and molecular drug susceptibility tests(DST) for patients with drug-resistant osteoarticular tuberculosis. Methods Using retrospective analysis, 112 cases of osteoarticular tuberculosis patients who received focal cleaning operation were enrolled between March to December 2018 in Chest Hospital of Xinjiang Uyghur Autonomous Region. BACTEC MGIT 960 and MTBDRplus-LPA were used for conducting DST. There were 23 drug-resistant patients detected by phenotypic and molecular DST. We then developed individualized anti-tuberculosis drug treatment plans for patients with drug-resistant osteoarticular tuberculosis based on DST results, and followed them up for 12 months, comparing a series of prognostic indicators (Imaging, ESR, CRP, VAS) for preoperative and follow-up periods to evaluate the effectiveness of treatment. Measurement data with normal distribution was expressed as “ $\bar{x}$±s”, comparison between groups was tested using ANOVA of repeated measurement data. Non-normal distribution was represented by “Median (IQR)”, comparison between groups was done with Friedman test. Statistically significance was set at P<0.05. Results Among 23 drug-resistant patients who had received individualized treatment for 12 months after surgery, 21 patients got improved, 1 patient had relapsed, and 1 patient was lost to follow-up. The bone graft fusion rate of 21 improved patients was 90.5% (19/21); The average ESR of 21 improved patients before surgery was (62.62±26.52) mm/1 h, the average CRP was (52.29±22.40) mg/L, the average VAS score was 7.0(6.0-7.5) points. After 12 months of personalized treatment, the average ESR dropped to (14.39±5.24) mm/1 h, which was significantly different from that before surgery (t=-8.25,P=0.000); The average CRP was (5.36±2.38) mg/L, had statistically significant difference compared with preoperative period (t=-9.65,P=0.000). Both indicators had returned to the normal range. The average VAS score dropped to 1.0(0.0-1.0)points, showing that symptoms of pain were greatly relieved, and there was a statistically significant difference from the preoperative score (q=7.30,P=0.000). Conclusion Phenotypic DST detection combined with molecular DST detection could help us to rapidly develop a comprehensive anti-tuberculosis drug treatment regimen. Postoperative reasonable and well-followed individualized anti-tuberculosis drug treatment is the key measure to cure osteoarticular tuberculosis.

      Comparative study of multislice spiral CT and color Doppler ultrasonography in the diagnosis of bone and joint tuberculosis
      ZHAO Tie-niu, JIANG Shuang-shuang, HUANG Li, HU Xue-mei
      Chinese Journal of Antituberculosis. 2020, 42(8):  845-849.  doi:10.3969/j.issn.1000-6621.2020.08.012
      Abstract ( 540 )   HTML ( 2 )   PDF (2566KB) ( 216 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To compare the effect of multislice spiral CT examination (CT examination) and color Doppler ultrasound (ultrasound examination) in the diagnosis of bone and joint tuberculosis. Methods Twenty-three cases of bone and joint tuberculosis from January 2015 to December 2019 were retrospectively analyzed. These cases were diagnosed by surgical pathology (9 cases), bacteriological diagnosis (10 cases) and clinical diagnosis (4 cases). Among them, there were 12 cases of simple bone tuberculosis, 9 cases of simple synovial tuberculosis, and 2 cases of total joint tuberculosis. CT examination and ultrasound examination were performed in all patients, and the diagnostic value of the two examination techniques for various types of bone and joint tuberculosis was analyzed. Results Accuracy of CT diagnosis of bone and joint tuberculosis was 65.2% (15/23) and ultrasound was 56.5% (13/23). There was no significant statistical difference between them (χ2=0.365, P=0.546). Accuracy of CT diagnosis of simple bone tuberculosis (83.3%, 10/12) was significantly higher than ultrasound (33.3%, 4/12), and there was significant statistical difference between them (χ2=6.171, P=0.013). In 9 cases of synovial tuberculosis, ultrasound correctly diagnosed 8 cases, CT correctly diagnosed 3 cases. In 2 cases of total joint tuberculosis, CT correctly diagnosed 2 cases, ultrasound correctly diagnosed 1 case. Conclusion For simple bone tuberculosis, CT examination is better than ultrasound. For simple synovial tuberculosis, ultrasound examination is better than CT examination.

      Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema
      DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning
      Chinese Journal of Antituberculosis. 2020, 42(8):  850-853.  doi:10.3969/j.issn.1000-6621.2020.08.013
      Abstract ( 424 )   HTML ( 9 )   PDF (793KB) ( 232 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective This study aimed to investigate the efficacy and safety of video-assisted thoracoscopic surgery (VATS) in the treatment of chronic tubercular empyema. Methods The clinical data of 82 patients with chronic tuberculous empyema treated in the Department of Thoracic Surgery, Xi’an Chest Hospital from January 2015 to December 2017 were retrospectively collected, including age, gender, course of disease, and lesions site. The patients were divided into VATS group (42 cases) and thoracotomy group (40 cases) according to the operation methods performed by the patients, and then the operation time, intraoperative blood loss, postoperative drainage volume, hospital stays, extubation time, complications, lung function recovery status (main indicators including forced vital capacity (FVC), 1st second forced expiratory volume in one second (FEV1), total lung capacity (TLC)), and relapse after 2 years of follow-up were compared. Results The intraoperative blood loss ((284.70±40.47) ml) and postoperative drainage volume ((687.40±78.58) ml) in the VATS group were significantly lower than the thoracotomy group ((309.90±58.82) ml and (748.00±65.22) ml, respectively), with the statistically significant differences (t=2.27 and 3.79, P=0.03 and 0.00, respectively); there were no significant differences in the operation time ((130.54±14.95) min vs (135.30±13.09) min), hospital stays ((12.30±2.54) d vs (11.70±2.06) d) and extubation time ((6.80±1.32) d vs (6.56±1.03) d) between the VATS group and thoracotomy group (t=1.53, 1.17, 0.92, P=0.13, 0.25, 0.36, respectively). The postoperative lung function indexes, such as FVC ((3.41±0.64) L), FEV1 ((3.45±0.56) L), and TLC ((5.82±0.87) L), in the VATS group were compared with the thoracotomy group ((3.26±0.89) L, (3.34±0.73) L, (5.78±0.35) L, respectively), and the differences were not statistically significant (t=0.79, 0.50, 0.26, P=0.43, 0.60, 0.81, respectively). The incidence of postoperative complications in the VATS group was 11.9% (5/42), which was significantly lower than 30.0% (12/40) in the thoracotomy group, with the statistically significant difference (χ2=4.08, P<0.05). After 2 years of follow-up, the recurrence rate in the thoracotomy group was 5.0% (2/40), while no recurrence was found in the VATS group, with no statistically significant difference between the two groups (χ2=2.15, P=0.14). Conclusion The patients with chronic tuberculous empyema underwent VATS show low intraoperative blood loss, postoperative drainage and postoperative complications, which is worthy of clinical application.

      Clinical characteristics of 19 infants with congenital tuberculosis and literature review
      XIA Lu, LU Shui-hua, LI Tao, LIU Xu-hui, LIU Ping, XI Xiu-hong
      Chinese Journal of Antituberculosis. 2020, 42(8):  854-857.  doi:10.3969/j.issn.1000-6621.2020.08.014
      Abstract ( 547 )   HTML ( 24 )   PDF (794KB) ( 272 )   Save
      References | Related Articles | Metrics

      Objective This study aimed to analyze the clinical characteristics of infants with congenital tuberculosis, and investigate the diagnosis and therapeutic schedule of congenital tuberculosis combined with the literature. Methods The data of 19 infants under the age of 6 months with congenital tuberculosis who were hospitalized in the Tuberculosis Department of Shanghai Public Health Clinical Center from January 2012 to September 2019 were collected, including age of onset, clinical manifestations, imaging and laboratory examination data, treatment and outcome, and then summarized combined with literature review. Results Among the 19 infants with congenital tuberculosis, there were 10 male (52.6%) and 9 female (47.4%), with the age of 3-60 days and the median age of 53 (30, 60) days; the shortest time of onset was 1 day after birth, and the longest was 45 days after birth, with the average onset time of (19.3±13.1) days. There were 10 cases (52.6%) with acute hematogenous disseminated tuberculosis, and 9 cases (47.4%) with primary tuberculosis; 9 cases (47.4%) had fever, and 8 cases (42.1%) had dyspnea and cyanosis. T-SPOT.TB test was positive in 9 cases (47.4%), and acid-fast staining smear and culture were positive in 6 cases (31.6%); GeneXpert MTB/RIF was performed in 17 cases, and 7 cases (41.2%) showed positive results. The chest CT imaging manifestations revealed 10 cases (52.6%) with diffuse miliary shadow of both lungs, 8 cases (42.1%) with local patchy shadow and enlargement of hilar lymph node, and 1 case (5.3%) with multiple patchy shadows of both lungs and pleural effusion; skull CT scanning showed 1 case (5.3%) with brain effusion; and gallbladder and spleen ultrasound examination showed hepatosplenomegaly in 9 cases (47.4%). All the infants received anti-tuberculosis treatment, and 17 cases recovered, 2 cases died. Conclusion The onset time of infants with congenital tuberculosis is usually within 2-4 weeks, the disease develops rapidly and critically, with a high mortality. Early positive anti-tuberculosis treatment plays a decisive role in the prognosis of infant with congenital tuberculosis.

      Effectiveness evaluation of referral and follow-up on WeChat using “Mobile Phone Integrated Management System for Tuberculosis Prevention and Treatment” for tuberculosis
      LI Xiao-fen, PENG Jian-ming, LIU Zhi-dong, WENG Jian-feng, XIAO San-hua, CHEN Wen-jie, WU Feng-xin
      Chinese Journal of Antituberculosis. 2020, 42(8):  858-862.  doi:10.3969/j.issn.1000-6621.2020.08.015
      Abstract ( 445 )   HTML ( 14 )   PDF (1110KB) ( 263 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Objective To evaluate the application effect of WeChat referral and WeChat follow-up functional modules of the “Mobile Phone Integrated Management System for Tuberculosis Prevention and Control” in Huizhou, and provide a basis for perfecting the system. Methods The lists of tuberculosis reporting units, suspicious tuberculosis patients and patients receiving treatment management in the “Tuberculosis Management Information System” of the Chinese Center for Disease Control and Prevention from 2016 to 2019 were collected, and then compared with the information of “Mobile Phone Integrated Management System for Tuberculosis Prevention and Control” to analyze the usage of institutions and patients. After the application of the WeChat referral and follow-up function, the 3883 suspicious patients referred by WeChat and 1960 patients followed by WeChat in 2018-2019 were served as the observation group, and the 12133 suspicious patients and 5643 patients before the application in 2016-2017 were used as the control group, and then the indicators of the patients between the two groups, including the number of referrals received, the number of follow-ups, the total number of patients in place, the number of patients who completed treatment, the number of lost patients, and the number of successful treatments, were compared and analyzed. The χ2 test was used for the comparison of various rates, and P<0.05 was considered statistically significant. Results (1) From 2018 to 2019, 41.5% (3883/9364) of suspected patients and 70.1% (96/137) of tuberculosis reporting agencies used WeChat referrals; 52.7% (1960/3722) of confirmed patients, and 100.0% (101/101) of tuberculosis designated medical institutions and primary medical and health institution used WeChat follow-up. (2) The referral rate of suspicious pulmonary tuberculosis patients in the observation group (100.0% (3883/3883)) was higher than that in the control group (62.8% (7614/12133)), with the statistically significant difference (χ2=2014.70, P<0.01); the tracking rate reached 100.0% (2077/2077) in the observation group, which was higher than that in the control group (99.1% (7519/7584)) (χ2=17.92, P<0.01); and the in-place rate in the observation group was higher than that in the control group (85.5% (3320/3883) vs 82.0% (9951/12133), χ2=25.16, P<0.01). (3) The loss rate of pulmonary tuberculosis patients in the observation group was lower than that in the control group (0.4% (7/1573) vs 1.8% (104/5643), χ2=15.87, P<0.01). Conclusion The application of WeChat referral and follow-up improved the referral rate, follow-up rate and in-place rate of suspicious tuberculosis patients, as well as reduced the loss rate of patients included in treatment management, and achieved good application results.

      Review Articles
      Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies
      YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying
      Chinese Journal of Antituberculosis. 2020, 42(8):  863-868.  doi:10.3969/j.issn.1000-6621.2020.08.016
      Abstract ( 769 )   HTML ( 26 )   PDF (829KB) ( 516 )   Save
      References | Related Articles | Metrics

      Tuberculosis (TB) remains one of the most severe single infectious diseases leading to high mortality in the world. Bacille Calmette-Guérin (BCG) is the only licensed preventive TB vaccine, which is routinely administered in newborns in high burden countries including China, and provides significant protection against TB. However, recent researches reveal that the protection provided by BCG is time-sensitive, especially declined in adults. Therefore, how to reform BCG to augment the protective immunity against TB becomes one of the principal strategies in the vaccine development and the prevention of infection. Herein, the authors will review the research progress to discuss about the current status in BCG vaccine development and vaccination strategies and their future application.

      Possible causes of infection after BCG vaccination
      CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui
      Chinese Journal of Antituberculosis. 2020, 42(8):  869-873.  doi:10.3969/j.issn.1000-6621.2020.08.017
      Abstract ( 637 )   HTML ( 10 )   PDF (820KB) ( 274 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Bacillus Calmette-Guérin (BCG) is an attenuated live bacterial vaccine used for prevention of tuberculosis. Although BCG is proven to be one of the safest vaccines, there are still some adverse reactions. The most severe complication is systemically disseminated BCG infection. Although incidence of BCG-related infections is low, the prognosis is poor and severe cases can be fatal. Therefore, strengthening the understanding of possible causes of BCG-related infections is important for improved BCG vaccination and clinical treatment of these infections.

      Research progress of carbohydrate metabolism of Mycobacterium tuberculosis
      QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei
      Chinese Journal of Antituberculosis. 2020, 42(8):  874-879.  doi:10.3969/j.issn.1000-6621.2020.08.018
      Abstract ( 525 )   HTML ( 9 )   PDF (1242KB) ( 374 )   Save
      Figures and Tables | References | Related Articles | Metrics

      Mycobacterium tuberculosis (MTB) is generally believed to preferentially rely on lipid metabolism to both establish and maintain chronic infections. However, the metabolic network of MTB can simultaneously catabolize multiple carbon substrates. The versatility of metabolism has been increasingly considered as an important pathogenic mechanism. Carbohydrate metabolism occupies a significant position in the pathogenesis of MTB, and complete carbohydrate metabolism plays an important role in maintaining the steady state of MTB. Based on MTB carbohydrate metabolism as a clue, the author sorts out and analyzes the transport and generation of sugar in MTB as well as the functional enzymes during the catabolism process, and explores the mechanism of carbohydrate metabolism to assist MTB in maintaining the homeostasis, so as to provide scientific basis for the research and development of new anti-tuberculosis drugs.

      In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria
      SUN Qing, HUANG Hai-rong, WANG Gui-rong
      Chinese Journal of Antituberculosis. 2020, 42(8):  880-884.  doi:10.3969/j.issn.1000-6621.2020.08.019
      Abstract ( 971 )   HTML ( 26 )   PDF (834KB) ( 430 )   Save
      References | Related Articles | Metrics

      Recently, the infection of non-tuberculous mycobacteria (NTM) has increased rapidly and threatened human health. NTM differentiate into many species. Species diversity makes treatment of NTM extremely difficult. Thus,it is very important to find new and effective drugs. Bedaquiline, clofazimine and delamanid showed effectiveness in treating NTM. In order to improve the understanding of drug susceptibility and drug resistance mechanism of NTM, in vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic are described.

Monthly, Established in Novembar 1934
ISSN 1000-6621
CN 11-2761/R

    Responsible Institution
    China Association for Science and Technology
    Sponsor
    Chinese Antituberculosis Association
    42 Dongsi Xidajie,Beijing 100710,China
    Editing
    Editorial Board of Chinese Journal of Antituberculosis
    5 Dongguang Hutong,Beijing 100035,China
    Tel(Fax): 0086-10-62257587
    http://www.zgflzz.cn
    Email: zgfIzz@163.com
    Editor-in-chief
    WANG Li-xia(王黎霞)
    Managing Director
    Ll Jing-wen(李敬文)
    Publishing
    Chinese Journal of Antituberculosis Publishing House
    5 Dongguang Hutong, Beijing 100035,China
    Tel(Fax):0086-10-62257257
    Email: zgflzz@163.com
    Printing
    Tomato Cloud Printing (Cangzhou) Co., Ltd.
    Overseas Distributor
    China International BookTrading Corporation
    P.O. Box 399,Beijing 100044,China
    Code No.M3721
Wechat